← All trials
NCT04712266
Early Phase 1Interventional
Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies).
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2020
- Primary completion
- Dec 15, 2020
- Completion date
- Jan 10, 2021
- First posted
- Jan 15, 2021
- Last posted
- Jan 15, 2021
- Enrollment
- 15
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Abvance TherapeuticsLead sponsor
- T1D Exchange, United StatesCollaborator
- Atlanta Diabetes AssociatesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.